← Back to Search

Procedure

LIMA to SVG Bridge Technique for Coronary Artery Disease (AMI-PONT Trial)

N/A
Waitlist Available
Led By Louis-Mathieu Stevens, MD, PhD (c)
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
require isolated CABG with median sternotomy on at least one left anterior descending (LAD) site and another anterolateral target;
provide written informed consent;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 and 5 years
Awards & highlights

AMI-PONT Trial Summary

This trial is comparing two different ways to do a CABG surgery - one where the mammary artery is used to supply blood to the entire anterolateral territory, and one where the mammary artery is used to supply blood to the left anterior descending coronary, with veins used for other target vessels.

AMI-PONT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

AMI-PONT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 and 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Anterolateral territory graft patency index
Assessment of grafts patency taken separately
Cardiovascular mortality
+2 more

AMI-PONT Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: LIMA to SVG BridgeExperimental Treatment1 Intervention
Patients will receive composite coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) and saphenous vein graft (SVG) Bridge for the anterolateral targets
Group II: Conventional CABGActive Control1 Intervention
Patients will receive conventional coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LIMA to SVG Bridge Technique
2012
N/A
~210

Find a Location

Who is running the clinical trial?

Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,333 Previous Clinical Trials
25,747,150 Total Patients Enrolled
25 Trials studying Coronary Artery Disease
29,270 Patients Enrolled for Coronary Artery Disease
Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
365 Previous Clinical Trials
129,101 Total Patients Enrolled
3 Trials studying Coronary Artery Disease
3,576 Patients Enrolled for Coronary Artery Disease
Louis-Mathieu Stevens, MD, PhD (c)Principal InvestigatorCentre Hospitalier de l'Universite de Montreal (CHUM)

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~16 spots leftby Mar 2025